-- Lumos Diagnostics Holdings (ASX:LDX) received a milestone payment of $507,377, under its contract with the Biomedical Advanced Research and Development Authority (BARDA) for achieving US Food and Drug Administration (FDA) CLIA waiver for its FebriDx rapid point-of-care test, according to a Thursday Australian bourse filing.
The receipt of the payment from BARDA brings the total amount received under the CLIA waiver study to almost $3 million.
Michael J. O'Sullivan, Senior Vice President, General Counsel and Secretary, on May 06, 2026, executed a purchase for 536 shares in Berkshire Hathaway (BRK.B) for $250,545. Following the Form 4 filing with the SEC, O'Sullivan has control over a total of 663 Class B common shares of the company, with 663 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1067983/000119312526209661/xslF345X05/ownership.xml
Dominic Ng, Director, Chief Executive Officer, on May 05, 2026, sold 30,000 shares in East West Bancorp (EWBC) for $3,704,700. Following the Form 4 filing with the SEC, Ng has control over a total of 745,706 common shares of the company, with 737,930 shares held directly and 7,776 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1069157/000120123626000010/xslF345X05/wk-form4_1778109841.xml
G. Staley Cates, Director, on May 06, 2026, executed a purchase for 1,500 shares in Affiliated Managers Group (AMG) for $458,745. Following the Form 4 filing with the SEC, Cates has control over a total of 6,405 common shares of the company, with 6,405 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1004434/000100443426000053/xslF345X05/form4.xml